SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Evel Knievel — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEvel Knievel
Date of birth1938-10-17
IdentifiersMRN HR-RB001-SYN-TD; SSN (made up) 000-01-4927
Document date1996-02-23
AuthorDale Rasmussen, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

First day of hepatitis C treatment. [S]

History of Present Illness

Mr. Knievel returns four weeks after the hepatology visit to start sofosbuvir-velpatasvir, which has been approved. He takes carvedilol 6.25 mg daily without dizziness. He has had one drink in the past month and wants to stop altogether. He started aquatic therapy three weeks ago and walks a little farther; pain is about 5 of 10. He has taken no omeprazole, ibuprofen or herbal products. He has had no low glucose readings, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. [S]

ElementDetail
TodayDay 1 of 12 weeks of sofosbuvir-velpatasvir
Carvedilol6.25 mg daily; pulse 68, blood pressure 128/78
AlcoholOne drink in the past month
Pain5 of 10 with aquatic therapy

Review of Systems

SystemResultFinding
ConstitutionalPositiveStill tired in the afternoons; no fever
GastrointestinalNegativeNo abdominal swelling, black stools or heartburn
CardiovascularNegativeNo dizziness on standing
MusculoskeletalPositiveHip and knee pain, 5 of 10; no muscle aches
EndocrineNegativeNo shakiness or sweating to suggest low glucose
PsychiatricNegativeMood steady; PHQ-9 5; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route1991-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route1994-06-01 to 1996-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route1994-06-01 to 1996-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route1996-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route1996-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26 to 1996-02-23completedS
Carvedilol 12.5 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26activeS
Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeksOne tablet daily for 12 weeksOral route1996-02-23 to 1996-05-17completedS
Cholecalciferol (vitamin D3) 50 mcg (1970 units) oral capsule, one capsule dailyOne capsule dailyOral route1996-02-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1996-02-23Body height178cmS
1996-02-23Body weight84.8kgS
1996-02-23Body mass index (BMI) [Ratio]26.8kg/m2S
1996-02-23Systolic blood pressure128mm[Hg]S
1996-02-23Diastolic blood pressure78mm[Hg]S
1996-02-23Heart rate68/minS
1996-02-23Respiratory rate14/minS
1996-02-23Body temperature36.6CelS
1996-02-23Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1996-02-23Hemoglobin [Mass/volume] in Blood14g/dL13.5-17.5 g/dLNormalS
1996-02-23Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
1996-02-23Platelets [#/volume] in Blood by Automated count12110*3/uL150-400 10*3/uLLowS
1996-02-23Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.74-1.35 mg/dLNormalS
1996-02-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-02-23Glucose [Mass/volume] in Serum or Plasma141mg/dL70-99 mg/dLHighS
1996-02-23Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma81U/L7-55 U/LHighS
1996-02-23Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma90U/L8-48 U/LHighS
1996-02-23Bilirubin.total [Mass/volume] in Serum or Plasma1mg/dL0.1-1.2 mg/dLNormalS
1996-02-23Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
1996-02-23Calcium [Mass/volume] in Serum or Plasma9.1mg/dL8.6-10.3 mg/dLNormalS
1996-02-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma17ng/mL30-100 ng/mLLowS
1996-02-23Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma388pg/mL232-1245 pg/mLNormalS
1996-02-23Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4.5 mIU/LNormalS
1996-02-23Total score [AUDIT-C]1{score}S
1996-02-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1996-02-23Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S

Physical Exam

Vital signs recorded on 1996-02-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 84.8 kg; blood pressure 128/78, pulse 68
SkinSpider angiomas unchanged; no jaundice or bruising
AbdomenSpleen tip palpable; no ascites
MusculoskeletalReduced hip rotation; knee crepitus; old forearm fracture deformities
NeurologicalNo asterixis

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1962 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cactiveconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL)activeconfirmed E55.9S — Synthetic finding before the bone density scan.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count, hepatic function panel and eGFRWithin three months before HCV treatmentCompleted todayHemoglobin 14.0 g/dL, white cells 4.8, platelets 121; creatinine 0.90 mg/dL, eGFR 100; ALT 81, AST 90 U/L, bilirubin 1.0 mg/dL, albumin 3.7 g/dL
LaboratoryINRWithin three months before HCV treatmentUp to date1.1 in January
Medication safetyDrug interaction reviewAt the start of HCV treatmentCompleted todayNo proton pump inhibitor, amiodarone or supplements; atorvastatin with muscle-pain monitoring
Medication safetyHypoglycemia monitoring on diabetes medicine during HCV treatmentThroughout treatmentCompleted todaySensor started; he knows how to treat a low
Medication safetyCarvedilol titrationEvery two to four weeks to the target doseCompleted todayRaised to 12.5 mg daily; pulse 68, blood pressure 128/78
Medication safetyHepatitis B vaccination, dose 2One month after dose 1Completed todayGiven today; series complete
LaboratoryVitamin D, calcium and TSH (secondary causes of bone loss)Before bone density testing in a man at riskCompleted todayVitamin D 17 ng/mL (low); calcium 9.1 mg/dL; TSH 2.1
LaboratoryVitamin B12 on long-term metforminPeriodicallyCompleted today388 pg/mL, normal
ImagingBone density (DXA)Men at risk: cirrhosis, alcohol and prior fracturesOrderedBooked in two weeks
ReferralPhysical therapyFor falls and chronic painUp to dateAssessed three weeks ago; aquatic therapy twice a week
ReferralDiabetic eye examinationYearlyReferredReferral made at the last visit; not yet booked
ExaminationSigns of decompensation (ascites, encephalopathy, jaundice, bleeding)Each visit in cirrhosisCompleted todayNone
SurveyAlcohol use (AUDIT-C)Each visit in liver diseaseCompleted todayAUDIT-C 1; he plans to stop
SurveyPain score and functionEach visitCompleted today5 of 10; walking farther
SurveyDepression screen (PHQ-9)At diagnosis and when treatment changesCompleted todayPHQ-9 5

Goal progress:

Immunizations given today: Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 2 of 2 [S]

Guideline basis: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025); de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021); Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022); American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Bone density scan in two weeks. Review at the end of 12 weeks of treatment. Call for jaundice, dark urine, abdominal swelling, black stools, confusion, faintness or low glucose readings. Next scheduled visit 1996-05-18: end of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinence. [S]